Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine.

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.